The Phase 2b/3 NAVIGATE study is a global, seamless, adaptive, randomized, placebo-controlled, double-blind trial. This is the first study of its kind in cirrhotic patients with an innovative ...

In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned symptomatic ... by a central or local institutional review board or ethics committee at each trial center.

The trial protocols were approved by the institutional review board or ethics committee ... randomized, double-blind, placebo-controlled phase 3 trials; an active drug control was also included ...

The pivotal Phase 3 DRAGON trial is a randomized, double-masked, placebo-controlled, global and multi-center study, designed to evaluate the safety and efficacy of Tinlarebant in adolescent ...

NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...

CHAPTER-3 is a randomized, double-blind, placebo-controlled Phase 3 study of orally administered ... by the International Accounting Standards Board. Pharvaris maintains its books and records ...